The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). For patients who have inadequately controlled rhinosinusitis and/or asthma despite treatment with topical corticosteroids and leukotriene-modifying drugs, aspirin desensitization is an important therapeutic option. This review examines the evidence supporting the effectiveness of aspirin desensitization for the treatment of chronic rhinosinusitis in patients with AERD. Practical aspects of conducting safe aspirin desensitization procedures and optimizing therapeutic benefits are also reviewed. When conducted in accordance with current guidelines, aspirin desensitization is a safe procedure that allows patients with AERD who have an indication for aspirin or other NSAIDs to safely ingest these medications. There is now strong evidence that aspirin desensitization and daily aspirin therapy is effective for treatment of the chronic inflammatory disease of the upper airway and lower airways in AERD.
- Stevenson D, Sanchez-Borges M, Szczeklik A: Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxegenase enzymes. Ann Allergy Asthma Immunol 2001, 87:177–180.
- Szczeklik A, Nizankowska E, Duplaga M: Natural history of aspirin-induced asthma. Eur Respir J 2000, 16:423–426. CrossRef
- Stevenson DD, Szczeklik A: Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006, 118:773–786. CrossRef
- Jenkins C, Costello J, Hodge L: Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004, 328:434. CrossRef
- Weber RW, Hoffman M, Raine DA, Nelson HS: Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 1979, 64:32–37. CrossRef
- Daffern P, Muilenberg D, Hugli TE, Stevenson DD: Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 1999, 104:559–564. CrossRef
- Bochenek G, Nagraba K, Nizankowska E, Szczeklik A: A controlled study of 9alpha11beta-PGF2 (a PGD2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenges. J Allergy Clin Immunol 2003, 111:743–749. CrossRef
- Sanak M, Levy BD, Clish CB, et al.: Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000, 16:44–49. CrossRef
- Schaefer D, Gode UC, Baenkler HW: Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur Respir J 1999, 13:638–646. CrossRef
- Szczeklik A: Prostaglandin E2 and aspirin-induced asthma. Lancet 1995, 345:1056. CrossRef
- Widal MF, Abrami P, Lermeyez J: Anaphylaxie et idiosyncrasie. Presse Med 1922, 30:189–192.
- Stevenson DD, Simon RA, Mathison DA: Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol 1980, 66:82–88. CrossRef
- Stevenson DD, Simon RA: Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol 2006, 118:801–804. CrossRef
- Macy E, Bernstein JA, Castells MC, et al.: Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol 2007, 98:172–174.
- Jenneck C, Juergens U, Buecheler M, Novak N: Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann Allergy Asthma Immunol 2007, 99:13–21.
- Picado C: Mechanisms of aspirin sensitivity. Curr Allergy Asthma Rep 2006, 6:198–202. CrossRef
- Mastalerz L, Milewski M, Duplaga M, et al.: Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. Allergy 1997, 52:895–900. CrossRef
- Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program; 2007. [NIH publication no. 08-4051.]
- Sladek K, Dworski R, Soja J, et al.: Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Resp Crit Care Med 1994, 149:940–946.
- Dahlen B, Nizankowska E, Szczeklik A, et al.: Benefits of adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998, 157:1187–1194.
- Dahlen S, Malstrom K, Nizankowska E, et al.: Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo controlled trial. Am J Respir Crit Care Med 2002, 165:9–14.
- Berges-Gimeno M, Simon RA, Stevenson DD: The natural history and clinical characteristics of aspirin exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002, 89:474–478.
- Slavin RG, Spector SL, Bernstein IL, et al.: The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol 2005, 116:S16–S47. CrossRef
- Samter M, Beers RF Jr: Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968, 68:975.
- McDonald JR, Mathison DA, Stevenson DD: Aspirin intolerance in asthma. J Allergy Clin Immunol 1972, 50:198. CrossRef
- Zeiss CR, Lockey RF: Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol 1976, 57:440. CrossRef
- Stevenson DD, Pleskow WW, Simon RA, et al.: Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984, 73:500–507. CrossRef
- Sweet JM, Stevenson DD, Simon RA, Mathison DA: Long-term effects of aspirin desensitization-treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 1990, 85:59–65. CrossRef
- Stevenson DD, Hankamer MA, Mathison DA, et al.: Aspirin desensitization of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996, 751–758.
- McMains KC, Kountakis SE: Medical and surgical considerations in patients with Samter’s triad. Am J Rhinol 2006, 20:573–576. CrossRef
- Berges-Gimeno MP, Simon RA, Stevenson DD: Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003, 111:180–186. CrossRef
- Berges-Gimeno MP, Simon RA, Stevenson DD: Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003, 90:338–341.
- Lee JY, Simon RA, Stevenson DD: Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007, 119:157–164. CrossRef
- Giampiero P, Bellioni P, Nucera E, et al.: Intranasal treatment with lysine acetylsalicylate in patients with nasal polyposis. Ann Allergy 1991, 67:588–592.
- Parikh AA, Scadding GK: Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope 2005, 115:1385–1390. CrossRef
- Ogata N, Darby Y, Scadding G: Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. J Laryngol Otol 2007, 121:1156–1160. CrossRef
- Lee JY, Simon RA: Does it make sense to “desens”? Aspirin desensitization in the treatment of chronic rhinosinusitis. Curr Allergy Asthma Reports 2006, 6:183–184. CrossRef
- Berges-Gimeno MP, Simon RA, Stevenson DD: The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002, 32:1491–1496. CrossRef
- White AA, Stevenson DD, Simon RA: The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005, 95:330–335. CrossRef
- Williams AN, Simon RA, Woessner KM, Stevenson DD: The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol 2007, 120:273–277. CrossRef
- Hooper L, Brown TJ, Elliott R, et al.: The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by nonsteroidal anti-inflammatory drugs: systematic review. BMJ 2004, 329:948. CrossRef
- The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis
Current Allergy and Asthma Reports
Volume 8, Issue 3 , pp 245-252
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Industry Sectors